A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 1200
Summary
- Conditions
- Atrial Fibrillation
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01493557
- Collaborators
- Not Provided
- Investigators
- Study Chair: Boehringer Ingelheim Boehringer Ingelheim